Clinuvel Pharmaceuticals Ltd CLVLY:OTCPK

RT Quote | Exchange | USD
Last | 9:30 AM EST
17.72quote price arrow up+0.77 (+4.54%)
Volume
3,710
52 week range
7.40 - 18.71

...

Loading . . .

KEY STATS

  • Open17.70
  • Day High17.79
  • Day Low17.70
  • Prev Close16.95
  • 52 Week High18.71
  • 52 Week High Date06/17/20
  • 52 Week Low7.40
  • 52 Week Low Date03/20/20
  • Market Cap837.51M
  • Shares Out49.41M
  • 10 Day Average Volume6,675.78
  • Dividend0.02
  • Dividend Yield0.10%
  • Beta0.53
  • 1 Year % Change62.67

RATIOS/PROFITABILITY

  • EPS (TTM)-
  • P/E (TTM)-
  • Fwd P/E (NTM)-
  • EBITDA (MRQ)-
  • ROE (MRQ)-
  • Revenue (MRQ)-
  • Gross Margin (MRQ)-
  • Net Margin (MRQ)-
  • Debt To Equity (MRQ)-

EVENTS

  • Earnings Date-
  • Ex Div Date09/04/2020
  • Div Amount0.0182
  • Split Date-
  • Split Factor-

Latest Clinuvel Pharmaceuticals Ltd News

There is no recent news for this security.

Latest CLVLY News From Our Partners

There is no recent news for this security.

QUOTE FINDER

Profile

MORE
Clinuvel Pharmaceuticals Ltd is a biopharmaceutical company. The Company is focused on developing and providing treatments for patients with a range of severe genetic and skin disorders. It is focused on developing and commercializing SCENESSE as a preventative therapy to photo-protect patients with erythropoietic protoporphyria (EPP). It is also focused on developing and commercializing SCENESSE as a combination therapy with narrowband ultraviolet B (NB-UVB) phototherapy for...
Willem Blijdorp
Non-Executive Chairman
Philippe Wolgen M.D.
Chief Executive Officer
Darren Keamy
Chief Financial Officer
Address
L 11 535 Bourke St
Melbourne, VIC
3000
Australia